Economic Impact of Hospitalizations in US Adults with Sarcopenia
Tóm tắt
Sarcopenia is characterized by progressive loss of muscle mass with corresponding decline in strength and/or physical function. The economic burden of sarcopenia-associated disability is considerable in the US. To estimate the cost of hospitalizations in US adults with sarcopenia categorized by age, sex, and race/ethnicity. A retrospective, prevalence based, economic burden study, consisting of 4011 adults aged ≥40 years with and without sarcopenia. Data on prevalence of low lean mass, functional limitations, and hospitalizations were obtained from the National Health and Nutrition Examination Survey (1999–2004); cost of hospitalizations was obtained from the Healthcare Cost and Utilization Project — National Inpatient Sample (2014), and population estimates were obtained from the US Census (2014). Probability and cost of hospitalizations were estimated by multiple logistic regression and negative binomial regression models, respectively. The total estimated cost of hospitalizations in individuals with sarcopenia was USD $40.4 billion with an average per person cost of USD $260. Within this category, average per person cost was highest for Hispanic women (USD $548) and lowest for Non-Hispanic Black women (USD $25); average per person cost was higher for older adults (≥65 years) (USD $375) than younger adults (40–64 years) (USD $204) with sarcopenia. The total cost of hospitalizations in individuals with sarcopenia (≥65 years) was USD $19.12 billion. Individuals with sarcopenia had greater odds of hospitalization (OR, 1.95; p<.001) compared to those without and had an annual marginal increase in cost of USD $2315.7 per person compared to individuals without sarcopenia. Sarcopenia places considerable economic burden on the US healthcare system. The ethnic disparity and economic burden associated with sarcopenia warrant further investigation.
Tài liệu tham khảo
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and ageing, 2018;48(1), 16–31.
Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–58.
Beaudart C, Rizzoli R, Bruyere O, Reginster JY, Biver E. Sarcopenia: burden and challenges for public health. Arch Public Health. 2014;72(1):45.
Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16:21.
Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res Rev. 2017;36:1–10.
United States Department of Agriculture Center for Nutrition Policy & Promotion. Process to Develop the 2020–2025 Dietary Guidelines for Americans https://doi.org/www.cnpp.usda.gov/sites/default/files/dietary_guidelines_for_americans/RevisedTopicsAndQuestions-ListA.pdf. Accessed 18 September 2018
Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531–2.
Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15(9):630–4.
Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P. Muscle dysfunction in cancer patients. Ann Oncol. 2014;25(5):947–58.
Souza VA, Oliveira D, Barbosa SR, et al. Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors. PLoS One. 2017;12(4):e0176230.
Feliciano EMC, Kroenke CH, Meyerhardt JA, et al. Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study. JAMA Oncol. 2017;3(12):e172319.
Silva AM, Shen W, Heo M, et al. Ethnicity-related skeletal muscle differences across the lifespan. Am J Hum Biol. 2010;22(1):76–82.
Kristy D, Goates S, Arensberg MB, Pereira S, Gaillard T. Prevalence of Sarcopenia and Sarcopenic Obesity Vary with Race/Ethnicity and Advancing Age. Diversity & Equality in Health and Care. 2018;15.
Kortebein P, Symons TB, Ferrando A, et al. Functional impact of 10 days of bed rest in healthy older adults. J Gerontol A Biol Sci Med Sci. 2008;63(10):1076–81.
Martone AM, Bianchi L, Abete P, et al. The incidence of sarcopenia among hospitalized older patients: results from the Glisten study. J Cachexia Sarcopenia Muscle. 2017; 8(6), 907–914.
Gariballa S, Alessa A. Sarcopenia: prevalence and prognostic significance in hospitalized patients. Clin Nutr. 2013;32(5):772–6.
Sousa AS, Guerra RS, Fonseca I, Pichel F, Amaral TF. Sarcopenia among hospitalized patients — A cross-sectional study. Clin Nutr. 2015;34(6):1239–44.
Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80–5.
National Center for Health Statistics. National Health and Nutrition Examination Survey 1600 Clifton Road Atlanta, GA2017 https://doi.org/www.cdc.gov/nchs/nhanes/index.htm. Accessed 1 September
Healthcare Cost and Utilization Project. NIS Overview. https://doi.org/www.hcup-us.ahrq. Accessed 13 July
Cost-to-Charge Ratio Files. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality Rockville, 2017 https://doi.org/www.hcup-us.ahrq.gov/db/state/costtocharge.jsp#user. Accessed 1 September
De Hoyos RE. SVYBSAMP2: Stata module to perform re-sampling for complex survey data. Boston College Department of Economics; 2005.
Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci. 2014;6:192.
Ortma JM, Velkoff VA, Hogan H. An Aging Nation: The Older Population in the United States: United States Census Bureau; 2014 https://doi.org/www.census.gov/prod/2014pubs/p25-1140.pdf.
Fitzpatrick AL, Powe NR, Cooper LS, Ives DG, Robbins JA. Barriers to health care access among the elderly and who perceives them. Am J Public Health. 2004;94(10):1788–94.
Sommers BD, Maylone B, Blendon RJ, Orav EJ, Epstein AM. Three-Year Impacts Of The Affordable Care Act: Improved Medical Care And Health Among Low-Income Adults. Health Aff (Millwood). 2017;36(6):1119–28.
Janes GR, Blackman DK, Bolen JC, et al. Surveillance for use of preventive health-care services by older adults, 1995–1997. MMWR CDC Surveill Summ. 1999;48(8):51–88.
Porell FW, Miltiades HB. Access to care and functional status change among aged Medicare beneficiaries. J Gerontol B Psychol Sci Soc Sci. 2001;56(2):S69–83.
Barne JC, Vornovitsky MS. Health Insurance Coverage in the United States: 2015 Current Population Reports: United States Census Bureau; 2016 https://doi.org/www.census.gov/content/dam/Census/library/publications/2016/demo/p60-257.pdf. Accessed 18 July
Escarce JJ, Kanika K. Access and Quality of Healthcare. 2006 In: Hispanics and Future of America [Internet]. Washington (DC): National Academic Press,. https://doi.org/www.ncbi.nlm.nih.gov/books/NBK19910/. Accessed 19 July 2017
Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014;43(6):748–59.
Deutz NE, Bauer JM, Barazzoni R, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929–36.
Centers for Disease Control and Prevention. Stopping Elderly Accidents, Deaths and Injury (STEADI). 2017 https://doi.org/www.cdc.gov/steadi/index.html.
World Health Organization. Integrated care for older people: guidelines on community-level interventions to manage declines in intrinsic capacity. 2017 https://doi.org/www.who.int/iris/handle/10665/258981. Accessed 18 September 2018